Psilocybin And Magic Mushrooms: Effects And Risks

à 27 avril

Psilocybin mushrooms, commonly known as magic mushrooms or shrooms, are a polyphyletic, informal group of fungi that contain psilocybin which turns into psilocin upon ingestion.Leading psychopharmacologist Roland Griffiths discloses the ways that psychedelic drugs can be used to create spiritually meaningful, personally...Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and psilocin are chemical compounds obtained from certain types of dried or fresh hallucinogenic Psilocybin is classified as an indole-alkylamine (tryptamine). These compounds have similar structure to lysergic acid diethylamide (LSD), and are...Psilocybin mushrooms are fungi that contain the psychoactive compound psilocybin, a naturally occurring psychedelic compound capable of producing powerful hallucinations and mystical-type experiences, along with other effects.Psilocybine is a tryptamine alkaloid, isolated from various genera of fungi including the genus Psilocybe, with hallucinogenic, anxiolytic, and psychoactive activities. In vivo, psilocybine is rapidly dephosphorylated into the active compound psilocin, which activates serotonin 2A (5-HT2A) receptors...

The science of psilocybin and its use to relieve suffering - YouTube

Psilocybin is a classic psychedelic, and thus activates a number of regions in the brain when it enters the human body. Psilocybin is able to activate a number of specific serotonin receptors that are called 5-HT2a receptors There are many different type of addiction, both neurochemical and psychological.Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social | Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |.Psilocybin is a naturally occurring psychedelic. It's illegal and not approved for medical use, but recent research has scientists intrigued. Psilocybin (chemically known as 4-phosphoryloxy-N, N-dimethyltryptamine) is a classic psychedelic that belongs to the group of hallucinogenic tryptamines.Psilocin and psilocybin, hallucinogenic principles contained in certain mushrooms, notably the Mexican species Psilocybe mexicana and Psilocybe cubensis. Psilocin and psilocybin alter the actions of the neurotransmitter serotonin in the brain.

Psilocybin (Magic Mushrooms) Uses, Effects & Hazards - Drugs.com

Psilocybin is a substance found in many species of mushrooms (often referred to as "magic mushrooms") that produces psychedelic effects. When this substance is ingested, it produces feelings of euphoria and sensory hallucinations that last for several hours. Some research suggests that when...Johnson: Psilocybin is a so-called classic psychedelic, so it's in the same category as drugs like LSD and works in the brain in basically the same way. Johnson: Because of that receptor activation, there is a profound change in the way that different areas of the brain synchronize with each other.Psilocybin definition is - a hallucinogenic indole C12H17N2O4P obtained from a fungus (such as Psilocybe mexicana or P. cubensis synonym Stropharia cubensis). Recent Examples on the Web Possession of a small quantity of psilocybin is a misdemeanor in Massachusetts.Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms. At present, assuming that the early clinical studies can be validated by larger studies, psilocybin is poised to make a significant impact on treatments...Psilocybe cyanescens. This specific type of psilocybin mushrooms are also known as "Wavy Caps". Please exercise maximum caution when it comes to cultivating or growing psilocybin mushrooms. There is a very real risk of poisoning and even death.

Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharm Ther. 2017;101:209–19.

CAS Article Google Scholar

Wasson RG. Notes on the present status of ololiuhqui and the other hallucinogens of Mexico. Botanical Mus Leafl Harv Univ. 1963;20:161–93.

CAS Google Scholar

Corne SJ, Pickering RW. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia. 1967;11:65–78.

CAS Article Google Scholar

Hofmann A, Heim R, Brack A, Kobel H. [Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim]. Experientia. 1958;14:107–9.

CAS Article Google Scholar

Hofmann A, Frey A, Ott H, Petrzilka T, Troxler F. [Elucidation of the structure and the synthesis of psilocybin]. Experientia. 1958;14:397–9.

CAS Article Google Scholar

Psilocybin. In: O'Neil MJ, editor. The Merck Index—An encyclopedia of chemicals, drugs, and biologicals,. 13th ed. Whitehouse Station, NJ: Merck and Co., Inc.; 2001. p. 1419.

Baker RW, Chothia C, Pauling P, Weber HP. Molecular structure of LSD. Science. 1972;178:614–5.

CAS Article Google Scholar

Beug MW, Bigwood J. Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, USA. J Ethnopharmacol. 1982;5:271–85.

CAS Article Google Scholar

Hofmann A. Teonanacatl and Ololuiqui and Ololuiqui, two ancient magic drugs of Mexico. Bull Narc. 1971;XXIII:3–14.

Google Scholar

10.

Horita A, Weber LJ. The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol. 1961;7:47–54.

CAS Article Google Scholar

11.

Horita A. Some biochemical studies on psilocybin and psilocin. J Neuropsychiatry. 1963;4:270.

CAS Google Scholar

12.

Hasler F, Bourquin D, Brenneisen R, Bar T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 1997;72:175–84.

CAS Article Google Scholar

13.

Nichols DE. Psychedelics. Pharm Rev.2016;68:264–355.

CAS Article Google Scholar

14.

Nichols DE, Frescas S. Improvements to the synthesis of psilocybin and a facile method for preparing the O-acetyl prodrug of psilocin. Synthesis. 1999;6:935–8.

Article Google Scholar

15.

Shirota O, Hakamata W, Goda Y. Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of "magic mushroom". J Nat Prod. 2003;66:885–7.

CAS Article Google Scholar

16.

Sherwood A, Meisenheimer P, Tarpley G, Kargbo R. An improved, practical, and scalable five-step synthesis of psilocybin. Synthesis. 2020;52:688–94.

CAS Article Google Scholar

17.

Kargbo R, Sherwood A, Kaylo K, Meisenheimer P, O'Hern K, Patterson T, et al. The First Direct Phosphorylation of Psilocin to Psilocybin under cGMP Conditions. International Society for Research on Psychedelics. New Orleans 2019.

18.

Agurell S, Nilsson JL. A biosynthetic sequence from tryptophan to psilocybin. Tetrahedron Lett. 1968;9:1063–4.

CAS Article Google Scholar

19.

Agurell S, Nilsson JL. Biosynthesis of psilocybin. II. Incorporation of labelled tryptamine derivatives. Acta Chem Scand. 1968;22:1210–8.

CAS Article Google Scholar

20.

Fricke J, Blei F, Hoffmeister D. Enzymatic synthesis of psilocybin. Angew Chem Int Ed Engl. 2017;56:12352–5.

CAS Article Google Scholar

21.

Adams AA, Kaplan NA, Wei Z, Brinton JD, Monnier CS, Enacopol AL, et al. In vivo production of psilocybin in E. coli. Metab Eng. 2019;56:111–9.

CAS Article Google Scholar

22.

Fricke J, Kargbo R, Regestein L, Lenz C, Peschel G, Rosenbaum M, et al. Scalable hybrid synthetic/biocatalytic route to psilocybin. Chemistry. 2020. https://doi.org/10.1002/chem.202000134.

23.

Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735–40.

CAS Article Google Scholar

24.

Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol. 2006;187:268–83.

CAS Article Google Scholar

25.

Maclean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25:1453–61.

CAS Article Google Scholar

26.

Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71–8.

CAS Article Google Scholar

27.

Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983–92.

Article Google Scholar

28.

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289–99.

CAS Article Google Scholar

29.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97.

CAS Article Google Scholar

30.

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165–80.

CAS Article Google Scholar

31.

Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997;16:357–72.

CAS Article Google Scholar

32.

Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999;20:565–81.

CAS Article Google Scholar

33.

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA. 2012;109:2138–43.

CAS Article Google Scholar

34.

Lewis CR, Preller KH, Kraehenmann R, Michels L, Staempfli P, Vollenweider FX. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage. 2017;159:70–8.

CAS Article Google Scholar

35.

Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D, et al. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013;33:15171–83.

CAS Article Google Scholar

36.

Beique JC, Imad M, Mladenovic L, Gingrich JA, Andrade R. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci USA. 2007;104:9870–5.

Article Google Scholar

37.

Martin DA, Nichols CD. Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain. EBioMedicine. 2016;11:262–77.

Article Google Scholar

38.

Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012;200:238–44.

CAS Article Google Scholar

39.

Petri G, Expert P, Turkheimer F, Carhart-Harris R, Nutt D, Hellyer PJ, et al. Homological scaffolds of brain functional networks. J R Soc Interface. 2014;11:20140873.

CAS Article Google Scholar

40.

Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:2214.

CAS Article Google Scholar